SOUTH SAN FRANCISCO, Calif. , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that Ascendas Genomics has received approval from the National Medical Products
Through an innovative and entrepreneurial approach to genomics medicine, the Centre intends to accelerate scientific discoveries. MELBOURNE, Australia and SOUTH SAN FRANCISCO, California, Sept. 4, 2015 – A partnership among Monash University, the University of Melbourne, the University of
Senior Biotechnology Leader with Broad Expertise in Life Science and Digital Health SOUTH SAN FRANCISCO, Calif. , July 25, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Bill W. Colston to the company’s Board of Directors.
Streamlines Operations to Reduce Hands-On Time, Accelerate Results Broad Menu of Applications with Automated Workflow Providing Sample-to-Answer Solutions on a Single Platform SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative
SOUTH SAN FRANCISCO, Calif. , April 23, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Brad Kreger as Senior Vice President, Global Operations. In this role, Kreger leads global manufacturing, supply chain, demand planning, and distribution for
Mass cytometry services for pharmaceutical and biotechnology companies to accelerate development of new health insights SOUTH SAN FRANCISCO, Calif. and MONTREAL , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory
SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Colin McCracken has joined the company as its Chief Commercial Officer. McCracken will be responsible for leading all commercial activities, driving revenue growth in new and
Speed and scale of Fluidigm microfluidics technology to facilitate early-stage host monitoring for COVID-19 SOUTH SAN FRANCISCO, Calif. , March 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Findings in Nature Communications Provide Insights That May Help Guide Patient Care Research Study Conducted in Collaboration with Fluidigm’s Therapeutic Insights Services SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
Industry-Leading CyTOF Technology Recognized at the 18th Annual HUPO World Congress for Delivering Unprecedented Proteomic Insight at Single-Cell Resolution SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Human Proteome Organization (HUPO), an international scientific
